Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT04945330

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Researchers want to learn more about the use of larotrectinib as a real-world treatment for tropomyosin receptor kinase fusion cancer, also called TRK fusion ca…

Japan100 participantsStarted 2021-11-05

Treatment: Larotrectinib (Vitrakvi, BAY2757556)

All recent trials (2 shown)

CompletedNot Applicable

NCT05793281

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied. In observational stud…

Japan46,621 participantsStarted 2023-03-10

Treatment: No Drug